VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
Janssen Research & Development, LLC
Milton S. Hershey Medical Center
Astellas Pharma Inc
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Artios Pharma Ltd
Centre Oscar Lambret
Memorial Sloan Kettering Cancer Center
Akeso
Eli Lilly and Company
Children's Oncology Group
Roswell Park Cancer Institute
Luye Pharma Group Ltd.
Institut du Cancer de Montpellier - Val d'Aurelle
Sun Yat-sen University
FBD Biologics Limited
Australian & New Zealand Children's Haematology/Oncology Group
Onconic Therapeutics Inc.
Gustave Roussy, Cancer Campus, Grand Paris
University of California, San Francisco
Zhejiang Doer Biologics Co., Ltd.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
University of Birmingham
Washington University School of Medicine
Sarcoma Alliance for Research through Collaboration
Merck Sharp & Dohme LLC
Thomas Jefferson University
Bristol-Myers Squibb
Chang Gung Memorial Hospital
National University Hospital, Singapore
PharmaMar
CARsgen Therapeutics Co., Ltd.
Nationwide Children's Hospital
Thomas Jefferson University
NuCana plc
HiberCell, Inc.
Fujian Cancer Hospital
Memorial Sloan Kettering Cancer Center
Biotech Pharmaceutical Co., Ltd.
Handok Inc.
Case Comprehensive Cancer Center
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Shanghai Junshi Bioscience Co., Ltd.
Immodulon Therapeutics Ltd
Memorial Sloan Kettering Cancer Center
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
Vanderbilt-Ingram Cancer Center
Milton S. Hershey Medical Center